Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies Generic Drugs

UK Prices Double For Multiple Molecules In December

Pricewatch UK – December 2022

  • Data

Executive Summary

Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.

You may also be interested in...



UK Prices See A Raft Of Rises In November

Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.

Celltrion And Rani Partner For Oral Adalimumab

Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies Generic Drugs
Latest Headlines

Celltrion And Rani Partner For Oral Adalimumab

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Neuraxpharm Brings In Greek Olanzapine Brand

See All
UsernamePublicRestriction

Register

GB152420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By